Search by Categories
- Insights
- Rare Disease
- Oncology
- Cell and Gene Therapy
- Medical Devices
- Consulting
- News & Analysis
-
Therapeutic Areas
Our expertise in the industry
FDA Approves BioXcel’s Agitation Drug Igalmi BioXcel Therapeutics has received FDA clearance for its first drug, Igalmi, as a treatment for agitation in persons with Schizophrenia or Bipolar Di...
Mental health services in the new technology-driven world offer so many options. Many of these options are accessible via intuitive apps that are designed to streamline the mental health journey a...
Depression is a global health burden and continues to increase with each passing day. As per the WHO, globally, more than 264 million people of all ages suffer from depression. It is one of the le...
Characterized by debilitating episodes of depression and mood elevation (mania or hypomania), Bipolar depression is an under-recognized and unappreciated phase of bipolar disorder. Since most pati...
Schizophrenia and Bipolar disorder (BD) are most of the times difficult to distinguish. Schizophrenia is characterized by hallucinations, and delusions when a patient loses reality and feels detac...
Bipolar Disorder is characterized by frequent-shifts in the mood and is a manic-depressive disorder hampering the routine life of an individual. According to the American Psychiatric Association, ...
Burn is a global public health problem, causing more than 180,000 deaths per year acros...
A Burn takes place when the skin comes into contact with a heat source. Burns can occur...
Pulmonary arterial hypertension is a progressive disease of the lung vascular system, p...
The Pharma and Biotech Healthcare market has been an ever-changing industry in terms of...
The organ on a chip is a microfluidic culture device that recapitulates the complicated...
Hear from our subject-matter experts and in-house KOL’s on Pharma and Healthcare market trends.
-Agonist.png "Toll-like Receptors Agonist")
